Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options. Here we discuss a novel therapeutic strategy to target CARM1-expressing ovarian cancer based on a combination of poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.

Keywords

• epithelial ovarian cancer
• poly (adp-ribose) polymerase (parp) inhibitors
• enhancer of zeste homology 2 (ezh2) inhibitors
• immune checkpoint blockers
• homologous recombination (hr)
• non-homologous end-joining (nhej)
• coactivator-associated arginine methyltransferase 1 (carm1)
• mitotic arrest deficient 2 like 2 (mad2l2)